文献速递前列腺癌

多参数磁共振成像在低危前列腺癌男性主动监测中的作用:一项成本效果建模研究

The Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Men with Low-risk Prostate Cancer: A Cost-effectiveness Modeling Study.
PubMed 文献 · Eur Urol Oncol · 2018-06-05

该研究采用马尔可夫队列模型,比较三种主动监测策略:经直肠超声引导活检、多参数磁共振成像联合磁共振超声引导活检、以及多参数磁共振成像不活检。结果显示,多参数磁共振成像联合活检策略成本更低且效果更高,相比经直肠超声引导活检具有成本效果;不活检策略效果更低。

要点

  • 多参数磁共振成像联合活检策略每例筛查男性预期平均成本为4848欧元,低于经直肠超声引导活检的5150欧元。
  • 多参数磁共振成像联合活检策略的QALY为18.67,高于经直肠超声引导活检的18.66。
  • 多参数磁共振成像不活检策略每例成本5994欧元,QALY为18.27,低于经直肠超声引导活检的18.66。

核心结论

  • 多参数磁共振成像联合磁共振超声引导活检似乎是低危前列腺癌男性最具成本效果的主动监测策略。

研究设计与样本

  • 开发了针对低危前列腺癌男性的马尔可夫队列模型,评估三种主动监测策略。
  • 输入数据来源于Meta分析、其他已发表文献和国家成本报告,采用欧洲医疗保健视角。

主要发现

  • 基础病例分析中,每例筛查男性预期平均成本:经直肠超声引导活检为5150欧元,多参数磁共振成像不活检为5994欧元,多参数磁共振成像联合活检为4848欧元。
  • 多参数磁共振成像联合活检相比经直肠超声引导活检QALY更高(18.67 vs 18.66)。
  • 多参数磁共振成像不活检相比经直肠超声引导活检QALY更低(18.27 vs 18.66)。
  • 由于成本更低且效果更高,多参数磁共振成像联合活检策略相比经直肠超声引导活检策略具有成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Active surveillance (AS) has limitations that include missing high-risk tumors and performing unnecessary biopsies. The use of multiparametric magnetic resonance imaging (mpMRI) in AS may overcome these limitations, but its cost-effectiveness remains uncertain. OBJECTIVE: To determine the cost-effectiveness of three AS strategies: AS with transrectal ultrasound-guided biopsy (TRUSGB), AS with mpMRI and MRI ultrasound-guided biopsy (MR-TRUSGB), and AS with mpMRI without biopsies. DESIGN, SETTING, AND PARTICIPANTS: A Markov cohort model for men with low-risk prostate cancer was developed to assess the three strategies. Input data were derived from meta-analysis, other published literature, and national cost reports. A health care perspective was used for a European setting. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Health care costs and quality-adjusted life years (QALYs) were modeled over a lifetime horizon. Deterministic and probabilistic sensitivity analyses were performed to address uncertainty in model parameters. RESULTS AND LIMITATIONS: In the base case analysis, expected mean costs per man screened were €5150 for TRUSGB, €5994 for mpMRI without biopsy, and €4848 for mpMRI with biopsy. Corresponding QALYs were higher for mpMRI with biopsy compared to TRUSGB (18.67 vs 18.66) and lower for mpMRI without biopsy compared to TRUSGB (18.27 vs 18.66). Owing to lower costs and higher effects, the mpMRI with biopsy strategy was cost-effective compared to the TRUSGB strategy. CONCLUSIONS: mpMRI with MR-TRUSGB appears to be the most cost-effective AS strategy for men with low-risk prostate cancer. PATIENT SUMMARY: We compared costs and quality of life for the standard active surveillance (AS) program for men diagnosed with low-risk prostate cancer to a monitoring program comprising multiparametric magnetic resonance imaging (mpMRI) with and without biopsies. Our results suggest that an AS strategy using mpMRI with biopsy improves quality of life and costs decrease. An AS strategy using mpMRI without biopsy was not beneficial compared to the standard program.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Patel S, Rongen JJ, Fütterer JJ, et al. The Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Men with Low-risk Prostate Cancer: A Cost-effectiveness Modeling Study. Eur Urol Oncol. 2018. PMID: 31158091. doi:10.1016/j.euo.2018.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。